Loading...
XSHE300702
Market cap741mUSD
Jan 10, Last price  
15.81CNY
1D
-1.31%
1Q
-2.53%
IPO
22.23%
Name

Zhejiang Tianyu Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300702 chart
P/E
198.74
P/S
2.15
EPS
0.08
Div Yield, %
0.00%
Shrs. gr., 5y
1.10%
Rev. gr., 5y
11.49%
Revenues
2.53b
-5.23%
723,249,900777,349,724840,085,2681,082,338,8231,188,282,8091,466,956,3812,110,595,6802,587,395,7112,545,009,5272,666,678,4712,527,270,111
Net income
27m
33,588,40024,139,82550,354,815122,337,689100,182,148163,661,953585,725,746667,060,796204,676,095027,359,257
CFO
-44m
39,731,80080,438,31614,751,417164,739,55688,516,86978,572,392427,836,939622,180,52000-43,904,902
Dividend
Jun 06, 20240.05 CNY/sh
Earnings
May 16, 2025

Profile

Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of cardiovascular, anti-diabetic, anti-atherosclerosis, anticoagulant, and anti-asthmatic series. It also provides fine chemicals and CMO services. The company was founded in 1993 and is based in Taizhou, China.
URL
http://www.tianyupharm.com/
IPO date
Sep 19, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,527,270
-5.23%
2,666,678
4.78%
Cost of revenue
1,959,796
2,384,179
Unusual Expense (Income)
NOPBT
567,474
282,500
NOPBT Margin
22.45%
10.59%
Operating Taxes
44,558
8,449
Tax Rate
7.85%
2.99%
NOPAT
522,916
274,051
Net income
27,359
 
Dividends
(34,798)
Dividend yield
0.39%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,524,881
1,122,145
Long-term debt
244,919
186,937
Deferred revenue
64,415
69,190
Other long-term liabilities
5,067
6,996
Net debt
1,253,794
741,115
Cash flow
Cash from operating activities
(43,905)
CAPEX
Cash from investing activities
(355,354)
Cash from financing activities
363,355
519,341
FCF
(15,807)
(142,426)
Balance
Cash
426,153
476,981
Long term investments
89,853
90,985
Excess cash
389,643
434,633
Stockholders' equity
1,981,962
2,097,418
Invested Capital
4,908,630
4,407,482
ROIC
11.23%
6.53%
ROCE
10.71%
5.82%
EV
Common stock shares outstanding
341,991
345,574
Price
21.71
-14.93%
25.52
-47.07%
Market cap
7,424,619
-15.81%
8,819,036
-47.28%
EV
8,678,412
9,560,151
EBITDA
872,600
537,439
EV/EBITDA
9.95
17.79
Interest
51,242
33,847
Interest/NOPBT
9.03%
11.98%